Roche Shares Might Struggle to Rise

Dow Jones11-02

1316 GMT - Roche Holding has benefited from a strong share rally over the past year that left it trading at a premium to European peers, but it might be hard to stretch this much further, UBS analysts say in a research note. While the Swiss drugmaker's medium-term prospects remain intact, this is now better captured by consensus estimates and the company's valuation, the analysts say. Breast-cancer drug giredestrant could generate multibillion-dollar annual sales, according to UBS. But beyond giredestrant's launch, Roche investors have limited updates to look forward to next year, the analysts add. UBS cuts its recommendation to neutral from buy and lifts its target price to 420 Swiss francs from 376 francs. Shares fall 1.5% to 397.50 francs, having risen 53% over the past year.

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment